The co
mpound (+)-2-(7-chloro-1,8-naphthyridin-2-yl)-3
S-(5-
methyl-2-oxohexyl)-1-isoindolinone (pagoclone) shows anxiolyticactivity due to partial agonis
m of the benzodiazepine site ofthe GABA
A receptor. We describe the develop
ment of anecono
mical and practical process for a 100+ kg pilot plantproduction used to supply develop
ment needs. For the keyreaction, a
![](/i<font color=)
mages/gifchars/beta2.gif" BORDER=0 ALIGN="
middle">-keto phosphoniu
m salt was prepared by selectivelyreacting a pri
mary
![](/i<font color=)
mages/gifchars/alpha.gif" BORDER=0>-bro
mo ketone with triphenylphosphinein the presence of a secondary
![](/i<font color=)
mages/gifchars/alpha.gif" BORDER=0>-bro
mo ketone. A novel Wittigreaction with a 1-isoindolinone was used to produce race
micpagoclone. The enantio
merically pure drug substance wasprepared by hydrolyzing a
![](/i<font color=)
mages/gifchars/ga
mma.gif" BORDER=0 >-lacta
m and resolving the resultingenantio
meric carboxylic acids with (+)-ephedrine he
mihydrate.An alternate resolution, involving chiral
multicolu
mn chro
matography (MCC) was also developed. The synthesis was co
mpleted by a race
mization-free lacta
m for
mation to affordpagoclone.